Imipenem + Cilastatin Iv Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Solutions
Available Strengths: 500 mg/500 mg, 1 g/1 g per vial
Reference Brands: Primaxin, Gemax (US & EU)
Category:
Antibiotics
Imipenem + Cilastatin inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, resulting in bacterial lysis. Cilastatin prevents renal degradation of imipenem, prolonging its activity. Benefits include rapid, broad-spectrum action against resistant bacteria, effective in severe infections like pneumonia and sepsis, with reliable bacterial eradication when used appropriately in clinical settings.
Imipenem + Cilastatin IV is available in Intravenous (IV) Solutions
and strengths such as 500 mg/500 mg, 1 g/1 g per vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Imipenem + Cilastatin IV is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Imipenem + Cilastatin IV can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Imipenem + Cilastatin intravenous (IV) is approved in both the EU and US for serious bacterial infections, including pneumonia, intra-abdominal, and urinary tract infections. In the EU, brands like Primaxin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical trial data; generic formulations are widely available. Both regions require comprehensive dossiers, including trial results, quality controls, and pharmacovigilance plans, for approval and safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access ensuring adherence to European and US standards for effective, safe antibacterial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing